RE: RNS!14 Jun 2019 08:25
This is fantastic news!
The fact these results are as expected, proves the theory of the steroid interference and therefore imo should open the potential market back to all sufferers not just those in the sub group we have discussed before.
“Dr Markku Jalkanen, Chief Executive Officer of Faron, said: "These YODA results once again are consistent with the INTEREST data, supporting the conclusion that co-administration of steroids with Traumakine in patients inhibited interferon beta action. These findings are significant in explaining the lack of clinical response to Traumakine in the INTEREST trial. The YODA report will become an essential part of our communication dossier with the FDA and EMA when we justify our clinical double dummy design for the concomitant use of steroids for the next Traumakine studies."